U.s. Stem Cell(OTC) USRM

Market Cap$600.00

Since IPO (2008)-100%

5 Year-100%

1 Year+0%

1 Month-99%

$0.00

+0.00%

+0.00Today

U.s. Stem Cell last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-24

U.s. Stem Cell stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-99%	USD 0.00	2026-07-16
1 month	-99%	USD 0.00	2026-06-22
3 month	+0%	USD 0.00	2026-04-23
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-07-22
3 year	-99.5%	USD 0.00	2023-07-25
5 year	-99.99%	USD 0.01	2021-07-23
Since inception	-100%	USD 5,000.00	2008-02-19

U.s. Stem Cell Financials at a Glance

Market Cap

$600.00

Revenue (TTM)

$82.05K

Net Income (TTM)

-$2.86M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-40.44 (Low)

Dividend

$0.00

Beta (Volatility)

-40.44 (Low)

Price

$0.00

Volume

54,804

Open

$0.00

Price

$0.00

Volume

54,804

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

-40.44 (Low)

Price

$0.00

Volume

54,804

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

USRM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About U.s. Stem Cell

U.S. Stem Cell, Inc. is a biotechnology firm focused on advancing and commercializing autologous cellular therapies in the United States. The company aims to address various medical conditions, including chronic heart damage and autoimmune disorders, through innovative treatments.

Products and Services

MyoCell: A therapy using a patient's muscle cells to regenerate heart scar tissue
AdipoCell: A cell therapy targeting acute myocardial infarction and ischemia
MyoCath: A specialized catheter for direct delivery of therapeutic cells into heart tissue

Growth Outlook

Expansion of clinical trials for MyoCell and AdipoCell is underway
Increasing demand for regenerative medicine solutions in healthcare
Potential partnerships with healthcare providers to enhance service offerings

Financial Highlights

Q4 2022 revenue of 19,974, showing a 40% increase from Q3 2022
Gross profit margin improved to 75% in Q4 2022
Operating expenses decreased by 5% compared to Q3 2022

U.S. Stem Cell, Inc. is positioned in a growing sector of biotechnology, focusing on innovative therapies that utilize the body's own cells. The company’s flagship products, MyoCell and AdipoCell, are designed to address significant health challenges, particularly in cardiac care. The recent financial performance indicates a positive trend, with increasing revenue and improving gross profit margins. The ongoing development of its product pipeline and potential partnerships may further enhance growth prospects. As the demand for regenerative medicine continues to rise, U.S. Stem Cell, Inc. is strategically positioned to capitalize on these opportunities.

AI Generated • Jul 27, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Miguel Tomás, MBA

Website

www.us-stemcell.com

Headquarters

Sunrise, FL 33323, US

USRM Financials

Key Financial Metrics (TTM)

Gross Margin

71.03%

Operating Margin

-2096.90%

Net Income Margin

-3483.21%

Return on Equity

20.78%

Return on Capital

N/A

Return on Assets

-4200.45%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$600.00

Shares Outstanding

641.51M

Volume

54.80K

Avg. Volume

38.04K

Financials (TTM)

Gross Profit

$58.28K

Operating Income

-$1.72M

EBITDA

-$2.02M

Operating Cash Flow

-$304.85K

Capital Expenditure

$0.00

Free Cash Flow

-$304.85K

Cash & ST Invst.

$5.13K

Total Debt

$8.95M

U.s. Stem Cell Performance Analysis

U.s. Stem Cell annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 200,749	N/A
2022	2022-12-31	USD 82,049	-59.1%

U.s. Stem Cell sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2022-03-31	-1.2%
Q2	2022-06-30	5.2%
Q3	2022-09-30	-41.9%
Q4	2022-12-31	40.2%

U.s. Stem Cell annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.01	N/A
2022	2022-12-31	USD -0.00	-32.4%

U.s. Stem Cell sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2022-03-31	-57.1%
Q2	2022-06-30	54.5%
Q3	2022-09-30	10.0%
Q4	2022-12-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2022YOY CHG

Revenue

$19.97K

-15.3%

Gross Profit

$15.05K

+0.6%

Gross Margin

75.36%

N/A

Market Cap

$600.00

N/A

Market Cap/Employee

$54.55

N/A

Employees

N/A

Net Income

-$566.62K

+11.6%

EBITDA

-$374.92K

-199.7%

Quarterly Fundamentals

Name

Q4 2022YOY CHG

Total Cash

$5.13K

-87.0%

Total Debt

$8.95M

+11.6%

Accounts Receivable

$4.33K

+257.1%

Inventory

$980.00

+149.4%

Long Term Debt

$682.04K

-5.5%

Short Term Debt

$8.26M

+13.4%

Return on Assets

-42.00%

N/A

Return on Invested Capital

12.28%

N/A

Free Cash Flow

-$43.07K

+80.1%

Operating Cash Flow

-$43.07K

+80.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IPAHInterpharm Holdings, Inc.

IPAHInterpharm Holdings, Inc.$0.00+0.00%

LADXLadRx Corporation

LADXLadRx Corporation$0.01-89.72%

AVXTAVAX Technologies, Inc.

AVXTAVAX Technologies, Inc.$0.00+0.00%

MHTXManhattan Scientifics, Inc.

MHTXManhattan Scientifics, Inc.$0.00+0.00%

DNAGDNAPrint Genomics, Inc.

DNAGDNAPrint Genomics, Inc.$0.00+0.00%

BRAXFBraxia Scientific Corp.

BRAXFBraxia Scientific Corp.$0.00+0.00%

MRPIMera Pharmaceuticals, Inc.

MRPIMera Pharmaceuticals, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PLTRPalantir Technologies

PLTRPalantir Technologies$162.66+0.29%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$125.33+0.09%

NVDANvidia

NVDANvidia$211.94+0.03%

INTCIntel

INTCIntel$100.86+0.11%

AMIXAutonomix Medical

AMIXAutonomix Medical$19.50+4.34%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.07+0.03%

NOKNokia

NOKNokia$9.92+0.06%

Questions About USRM

What is the current price of U.s. Stem Cell?

U.s. Stem Cell is trading at $0.00 per share.

What is the 52-week range for U.s. Stem Cell?

Over the past 52 weeks, U.s. Stem Cell has traded between $0.00 and $0.00.

How much debt does U.s. Stem Cell have?

As of the most recent reporting period, U.s. Stem Cell reported total debt of $8.95M.

How much cash does U.s. Stem Cell have on hand?

U.s. Stem Cell reported $5.13K in cash and cash equivalents in its most recent financial results.

What is U.s. Stem Cell’s dividend yield?

U.s. Stem Cell does not currently have a dividend yield.

U.s. Stem Cell(OTC) USRM

U.s. Stem Cell Financials at a Glance

USRM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About U.s. Stem Cell

USRM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

U.s. Stem Cell Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About USRM

What is the current price of U.s. Stem Cell?

What is the 52-week range for U.s. Stem Cell?

How much debt does U.s. Stem Cell have?

How much cash does U.s. Stem Cell have on hand?

What is U.s. Stem Cell’s dividend yield?

Premium Investing Services